Early M&A: The Secret of Biotech's Success

As a product-focused biotech with two clinical phase cancer compounds ready to out-license, Wilex stands apart from most of its German--and European--peers. It has got to where it is by virtue of tight focus cost control and an early openness to M&A. Wilex now needs to show it can sign the sort of deals it needs to get to the next level.

Founded in 1998, Wilex AG was one of the first products of the government-funded biotech splurge which kick-started the German biotech industry. But Wilex's product focus and strong cost-control distinguished it from the outset from most of its peers. Reflecting their country's research predilections, most German biotechs were built to offer discovery services based around their technology platforms.

Few investors or entrepreneurs had been through a full round of biotech investment cycles and they thus saw little reason...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Global Vision

More from In Vivo